日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial

Praluzatamab Ravtansine(一种靶向 CD166 的抗体药物偶联物)用于治疗晚期实体瘤患者:一项开放标签 I/II 期试验

Valentina Boni, Mary J Fidler, Hendrik-Tobias Arkenau, Alexander Spira, Funda Meric-Bernstam, Nataliya Uboha, Rachel E Sanborn, Randy F Sweis, Patricia LoRusso, Misako Nagasaka, Javier Garcia-Corbacho, Shadia Jalal, James J Harding, Stella K Kim, Iris H C Miedema, Danielle J Vugts, Marc C Huisman, G

Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma

galunisertib 和 ramucirumab 治疗晚期肝细胞癌患者的 1b 期研究

James J Harding, Richard K Do, Amin Yaqubie, Ann Cleverly, Yumin Zhao, Ivelina Gueorguieva, Michael Lahn, Karim A Benhadji, Robin K Kelley, Ghassan K Abou-Alfa

In situ vaccination with defined factors overcomes T cell exhaustion in distant tumors

用特定因子进行原位疫苗接种可克服远处肿瘤中的 T 细胞耗竭

Danny N Khalil, Nathan Suek, Luis Felipe Campesato, Sadna Budhu, David Redmond, Robert M Samstein, Chirag Krishna, Katherine S Panageas, Marinela Capanu, Sean Houghton, Daniel Hirschhorn, Roberta Zappasodi, Rachel Giese, Billel Gasmi, Michael Schneider, Aditi Gupta, James J Harding, John Alec Moral,

Human cytomegalovirus decreases constitutive transcription of MHC class II genes in mature Langerhans cells by reducing CIITA transcript levels

人类巨细胞病毒通过降低 CIITA 转录水平来降低成熟朗格汉斯细胞中 MHC II 类基因的组成性转录

Andrew W Lee, Nan Wang, Tara M C Hornell, James J Harding, Chetan Deshpande, Laura Hertel, Vashti Lacaille, Achal Pashine, Claudia Macaubas, Edward S Mocarski, Elizabeth D Mellins